Evidence map›Paper›PMID 36983571›Full record

ReviewJournal of personalized medicine2023

Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis.

Md Abdus Subhan, Farzana Parveen, Nina Filipczak, Satya Siva Kishan Yalamarty, Vladimir P Torchilin

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of personalized medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 1 pooled it
25.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 1 synthesis or guideline pooled it, 70 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Development of radiolabeledJournal of cancer research and clinical oncology · 2026
    Article
  10. Article
  11. Tumor-Targeted Delivery Therapy Based on PLGA Nanoparticles.Journal of functional biomaterials · 2026
    Review
  12. Article
  13. Applications of Nanobiotechnology in Medicine.Life (Basel, Switzerland) · 2026
    Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 3 countries.

Md Abdus SubhanDepartment of Chemistry, ShahJalal University of Science and Technology, Sylhet 3114, Bangladesh.ORCID 0000-0002-5623-7643
Farzana ParveenCPBN, Department of Pharmaceutical Sciences, Northeastern University, Boston, MA 02115, USA.ORCID 0000-0002-3292-3841
Nina FilipczakCPBN, Department of Pharmaceutical Sciences, Northeastern University, Boston, MA 02115, USA.ORCID 0000-0001-9285-8298
Satya Siva Kishan YalamartyCPBN, Department of Pharmaceutical Sciences, Northeastern University, Boston, MA 02115, USA.ORCID 0000-0002-2941-0754
Vladimir P TorchilinCPBN, Department of Pharmaceutical Sciences, Northeastern University, Boston, MA 02115, USA.
Northeastern University · USShahjalal University of Science and Technology · BD

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The innovative development of nanomedicine has promised effective treatment options compared to the standard therapeutics for cancer therapy. However, the efficiency of EPR-targeted nanodrugs is not always pleasing as it is strongly prejudiced by the heterogeneity of the enhanced permeability and retention effect (EPR). Targeting the dynamics of the EPR effect and improvement of the therapeutic effects of nanotherapeutics by using EPR enhancers is a vital approach to developing cancer therapy. Inadequate data on the efficacy of EPR in humans hampers the clinical translation of cancer drugs. Molecular targeting, physical amendment, or physiological renovation of the tumor microenvironment (TME) are crucial approaches for improving the EPR effect. Advanced imaging technologies for the visualization of EPR-induced nanomedicine distribution in tumors, and the use of better animal models, are necessary to enhance the EPR effect. This review discusses strategies to enhance EPR effect-based drug delivery approaches for cancer therapy and imaging technologies for the diagnosis of EPR effects. The effort of studying the EPR effect is beneficial, as some of the advanced nanomedicine-based EPR-enhancing approaches are currently undergoing clinical trials, which may be helpful to improve EPR-induced drug delivery and translation to clinics.

Indexed as

clinical trialsEPR-based therapyEPR enhancersheterogeneitynanomedicinepassive targetingsolid tumor

Identifiers

PMID36983571
PMCPMC10051487
OpenAlexW4321601715

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.